During a widely anticipated U.K. Parliamentary hearing, Vertex (VRTX) Pharmaceuticals (VRTX) chief executive Jeff Leiden promised to offer “new ideas” for breaking a long-running stalemate over access to a cystic fibrosis medicine when he meets with a government official next week.

“I’m going to come to the meeting with new ideas,” Leiden said about his planned meeting on Monday with Secretary of State Matt Hancock. “And meantime, we would guarantee access to patients at a discount to our list price. I want to get (a pair of government health agencies) back to the table. There’s no reason we can’t find a solution here in England.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy